All In Biotech

Drug Trial Radar · NCT05676749

C-TIL051 in Non-Small Cell Lung Cancer

C-TIL051 in Anti-PD1 Resistant Metastatic Non-Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Jan 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

1

Actual

Start

Feb 29, 2024

Primary completion

Dec 30, 2025

Study completion Dec 30, 2025

Sponsor

Lead sponsor
AbelZeta Inc.Industry
Sponsor type
Industry
Collaborators
Nektar Therapeutics
First posted
Jan 9, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this Phase 1 clinical study is test tumor infiltrating lymphocytes (known as C-TIL051) with NKTR-255 and anti-PD1 therapy for subjects with refractory non-small cell lung cancer. The purpose of this study is to: 1. Test the safety and ability for subjects to tolerate the TIL therapy 2. Measure to see how the NSCLC responds to the TIL therapy Participants will be asked to: * Provide a tumor sample prior to the start of any treatment which will be used to make the C-TIL051. * Receive standard of care treatment until their lung cancer no longer responds * When necessary, the C-TIL051 will be manufactured by the sponsor and sent back to the site * Subject will then receive chemotherapy (called lymphodepletion) for 3 days followed by 2 days of rest * C-TIL051 will then be infused on day 0 followed by NKTR-255 (IL-15) about 12 to 24 hours later * Pembrolizumab will be administered every 3 weeks for up to 2 years NKTR-255 is a novel polymer-conjugated human IL-15 receptor agonist molecule designed to increase the proliferation and survival of memory CD8+ T cells and enhance the formation of long-term immunological memory which may lead to sustained anti-cancer immune response. The combination of NKTR 255 and TIL's could improve proliferation and persistence of cellular therapies leading to enhanced anti-tumor activity.

Conditions

  • Metastatic Non Small Cell Lung Cancer

Interventions

  • C-TIL051Biological

    C-TIL051 given in combination with IL-15 (NKTR-255) and pembrolizumab

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Calculate the Incidence of Adverse Events or Dose Limiting ToxicitiesTime frame: up to 24 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Ochsner MD Anderson Cancer Center

    New Orleans, Louisiana

  • Duke Center for Cancer Immunotherapy

    Raleigh, North Carolina

  • Allegheny Health Network-West Penn Hospital

    Pittsburgh, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.